Episodes (Page 5)
✨
Optimizing clinical trials through smarter outsourcing and patient-focused design.
Carrie Melvin
Claire Riches
✨
Industry addresses Most Favored Nation (MFN) policy impacts.
✨
Impact of FDA senior leadership changes following Commissioner's resignation.
Derrick Gingery
Maaisha Osman
Nielsen Hobbs
Sue Sutter
✨
MHRA updates on CE marking and pre-market submission timelines.
Ashley Yeo
Rob Reid
✨
Europe is becoming a key hub for clinical trial innovation and patient recruitment.
Andrew Warmington
Scott Davis
✨
Ovid Therapeutics Chairman views US biotech sector as a strategic national asset.
✨
GSK strengthens its obesity strategy; Novo Nordisk leads in early oral obesity drugs.
✨
GSK bolsters its obesity strategy; Novo Nordisk leads in early oral obesity drugs.
✨
Steve Lee discussed the MHRA's 2026 CE-marking consultation and UK medtech regulations.
Steve Lee
✨
Analysis of Martin Makary's resignation as FDA Commissioner and key mistakes.
Mike McCaughan
✨
Medicines for Europe biosimilars conference discussed market dynamics.
Dave Wallace
Dean Rudge
✨
Kurma Partners closed BioFund IV at €215m, falling short of its target.
Amanda Gett-Chaperot
✨
Episode: The Scrip Awards Podcast - Call For Entries 2026, New AI Category, Triana Interview
✨
Arcutis CEO discusses building a patient-first culture in immunodermatology.
Frank Watanabe
✨
Volker Spitzer explored agentic AI's impact on the consumer health industry.
Volker Spitzer
✨
Novo Nordisk leads in oral obesity drugs; GSK strengthens its strategy.
✨
Novo Nordisk leads in oral obesity drugs; GSK strengthens its strategy.
✨
Pressure mounts for FDA Commissioner Makary to resign amid reform efforts.
✨
Gwyn Tudor highlighted opportunities for healthtech founders in Wales.
Gwyn Tudor
✨
Katherine Szarama appointed acting CBER director; permanent director search timeline updated.